LongeVC | Competitive Intelligence Profile LongeVC is a venture capital firm based in Lugano, Switzerland, founded in 2016. The company specializes in supporting early-stage...
LongeVC | Competitive Intelligence Insights - Apr 16, 2025 Dr. John Mikhael joins LongeVC's advisory board on April 14, 2025, enhancing focus on AI-driven diagnostics and Boston-based innovation...
LongeVC | Competitive Intelligence Insights - Apr 01, 2025 LongeVC invested in the British startup BioConstructiv, a company specializing in synthetic biology and biotechnology....
LongeVC | Competitive Intelligence Insights - Mar 25, 2025 Garri Zmudze, a Longevity and biotech VC, highlighted LongeVC's focus on diagnostics with portfolio companies like AOA Dx, Melio, Deep Longevity, SiPhox Health, PreComb, and Haut.AI...
LongeVC | Competitive Intelligence Insights - Mar 12, 2025 LongeVC has topped up the investment in their portfolio company SiPhox Health to make at-home blood testing more accessible and user-friendly...
LongeVC | Competitive Intelligence Insights - Mar 04, 2025 LongeVC has backed SiPhox Health, a portfolio company, in its latest funding round as SiPhox doubled its revenue in 2024 and advanced in product development and R&D...
LongeVC | Competitive Intelligence Insights - Feb 14, 2025 LongeVC's portfolio company HautAI launched SkinGPT, an AI platform for personalized virtual skincare try-ons, using generative AI to simulate product effects and skin changes...
LongeVC | Competitive Intelligence Insights - Feb 03, 2025 Unnatural Products Inc., a LongeVC portfolio company, is pioneering AI-powered macrocyclic molecule design in collaboration with Merck to enhance drug discovery for complex diseases...
LongeVC | Competitive Intelligence Insights - Jan 22, 2025 LongeVC's portfolio company Melio, led by Mridu Sinha, received a $3.5M grant to develop a platform for rapid identification of bloodstream infections, starting with neonatal sepsis...
LongeVC | Competitive Intelligence Insights - Jan 14, 2025 LongeVC's comparative indices for 2023 show slight improvements in net turnover, equity capital, fixed assets, balance, tangible assets, and liquidity...